Press release
Chronic Urticaria Pipeline: Unleashing Hope with 20+ Innovators like UCB Biopharma, GI Innovation, Celldex Therapeutics, and Eli Lilly Crafting Bold New Therapies
Chronic Urticaria Pipeline
DelveInsight's 'Chronic Urticaria Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Chronic Urticaria or Hives therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Chronic Urticaria or Hives pipeline domain.
For emerging Chronic Urticaria or Hives drugs, the Chronic Urticaria or Hives pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Chronic Urticaria or Hives Pipeline Report
• DelveInsight's Chronic Urticaria or Hives Pipeline analysis depicts a robust space with 20+ active players working to develop 22+ pipeline drugs for Chronic Urticaria or Hives treatment.
• The leading Chronic Urticaria or Hives companies include Novartis, Synermore Biologics, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Celltrion, United BioPharma, Glenmark Pharmaceuticals, UCB Biopharma, GI Innovation, Celldex Therapeutics, Eli Lilly and Company, Amgen, ValenzaBio, Third Harmonic Bio, Inmagene, Lanier Biotherapeutics, and others are evaluating their lead assets to improve the Chronic Urticaria or Hives treatment landscape.
• Key Chronic Urticaria or Hives pipeline therapies in various stages of development include SYN008, Povorcitinib, Briquilimab, Remibrutinib, DUPIXENT, FASENRA, Lirentelimab, TEZSPIRE, Rilzabrutinib, TAS5315, Barzolvolimab, and others.
• In November 2024, the FDA accepted the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric patients aged 12 and older with chronic spontaneous urticaria (CSU) inadequately controlled by H1 antihistamines.
Request a sample and discover the recent breakthroughs happening in the Chronic Urticaria or Hives pipeline landscape @ https://www.delveinsight.com/report-store/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Urticaria or Hives Overview
Chronic urticaria (CU) is a skin condition marked by hives or wheals lasting over six weeks, causing persistent itching and discomfort that impacts quality of life. It may be idiopathic or linked to underlying issues. Symptoms include raised, itchy welts that vary in size and location, intense itching (often worse at night), swelling (angioedema) around the eyes, lips, or throat, and frequent hives for weeks. Triggers can involve autoimmune factors (autoantibodies activating histamine release), physical stimuli (pressure, temperature, exercise), infections (e.g., Helicobacter pylori), rare allergens, or conditions like thyroid disease or lupus.
CU's pathophysiology involves immune cells like mast cells and basophils releasing histamine and inflammatory cytokines (e.g., IL-4, IL-13), causing vasodilation, swelling, and itching. Autoantibodies may target IgE receptors in some cases. Diagnosis relies on patient history and physical exams, assessing hive duration, triggers, and symptoms. Tests like CBC, ESR, thyroid function, or ASST may identify underlying causes.
Treatment starts with non-sedating H1 antihistamines, escalating to H2 antihistamines or leukotriene antagonists if needed. Severe cases may require omalizumab or immunosuppressants like cyclosporine. Short-term corticosteroids help acute flares, but long-term use is avoided. Avoiding triggers is key.
Find out more about Chronic Urticaria or Hives medication @ https://www.delveinsight.com/report-store/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Urticaria or Hives Treatment Analysis: Drug Profile
SYN008: Synermore Biologics
SYN008 is a biosimilar to Omalizumab (Xolair), a humanized monoclonal antibody targeting free IgE in the blood. By binding IgE, it prevents its interaction with effector cells, halting allergic responses regardless of the allergen. Extensive comparability studies with Omalizumab were completed, and an investigational new drug (IND) application was submitted to the China Food and Drug Administration (CFDA) in October 2014. Phase I trials concluded in Australia by September 2016, and SYN008 is now in Phase III development for treating chronic urticaria.
Povorcitinib: Incyte Corporation
Povorcitinib (INCB54707) is an oral, selective JAK1 inhibitor currently in Phase III trials for hidradenitis suppurativa (HS) and vitiligo, with a Phase III trial planned for prurigo nodularis (PN). It is also under evaluation in Phase II studies for PN, asthma, and chronic spontaneous urticaria. Protected by compound and use patents in select regions, povorcitinib is in Phase II development for chronic urticaria treatment.
Key Chronic Urticaria or Hives Therapies and Companies
• SYN008: Synermore Biologics
• Povorcitinib - Incyte Corporation
• Briquilimab: Jasper Therapeutics
• Remibrutinib (LOU064): Novartis Pharmaceuticals
• DUPIXENT (dupilumab): Sanofi/Regeneron
• FASENRA (benralizumab): AstraZeneca/Kyowa Hakko Kirin
• Lirentelimab (AK002): Allakos/BioWa
• TEZSPIRE (tezepelumab): AstraZeneca/Amgen
• Rilzabrutinib (SAR444671): Sanofi
• TAS5315: Taiho Pharmaceutical
• Barzolvolimab (CDX-0159): Celldex Therapeutics
Learn more about the novel and emerging Chronic Urticaria or Hives pipeline therapies @ https://www.delveinsight.com/report-store/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Urticaria or Hives Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Scope of the Chronic Urticaria or Hives Pipeline Report
• Coverage: Global
• Key Chronic Urticaria or Hives Companies: Novartis, Synermore Biologics, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Celltrion, United BioPharma, Glenmark Pharmaceuticals, UCB Biopharma, GI Innovation, Celldex Therapeutics, Eli Lilly and Company, Amgen, ValenzaBio, Third Harmonic Bio, Inmagene, Lanier Biotherapeutics, and others.
• Key Chronic Urticaria or Hives Pipeline Therapies: SYN008, Povorcitinib, Briquilimab, Remibrutinib, DUPIXENT, FASENRA, Lirentelimab, TEZSPIRE, Rilzabrutinib, TAS5315, Barzolvolimab, and others.
Dive deep into rich insights for drugs used for Chronic Urticaria or Hives treatment; visit @ https://www.delveinsight.com/report-store/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Chronic Urticaria or Hives Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Chronic Urticaria or Hives Pipeline Therapeutics
6. Chronic Urticaria or Hives Pipeline: Late-Stage Products (Phase III)
7. Chronic Urticaria or Hives Pipeline: Late-Stage Products (Phase III)
8. Chronic Urticaria or Hives Pipeline: Mid-Stage Products (Phase II)
9. Chronic Urticaria or Hives Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Urticaria Pipeline: Unleashing Hope with 20+ Innovators like UCB Biopharma, GI Innovation, Celldex Therapeutics, and Eli Lilly Crafting Bold New Therapies here
News-ID: 3933699 • Views: …
More Releases from DelveInsight
Candidiasis Clinical Trials Analysis 2025: Oral Agents, Next-Generation Echinoca …
DelveInsight's "Candidiasis - Clinical Trials Analysis, 2025" examines an active clinical landscape addressing both mucosal (vulvovaginal) and invasive candidiasis. Unmet needs for safe, oral, and resistance-resilient therapies have driven the development of therapies across multiple modalities - new oral triterpenoids and azoles for recurrent vulvovaginal candidiasis (RVVC), next-generation echinocandins for candidemia/invasive candidiasis, and first-in-class broad-spectrum agents for drug-resistant and systemic infections. Regulatory progress and late-stage trials over the past few…
Necrotizing Enterocolitis Clinical Trials Analysis 2025: Probiotics, HMOs, and R …
DelveInsight's "Necrotizing Enterocolitis (NEC) - Clinical Trials Analysis, 2025" highlights an evolving pipeline aimed at reducing NEC incidence and severity in preterm infants. With NEC remaining a leading cause of neonatal morbidity and mortality, clinical studies are shifting toward microbiome-based prevention, human milk-derived biologics, and regenerative approaches.
Probiotic regimens containing Bifidobacterium and Lactobacillus strains are showing consistent efficacy in lowering NEC rates and mortality, driving wider adoption in NICUs. Parallel trials…
Brain Hemorrhage Clinical Trials Analysis 2025: Hemostasis, Neuroprotection, and …
DelveInsight's "Brain Hemorrhage - Clinical Trials Analysis, 2025" surveys an active acute-care landscape focused on reducing hematoma expansion, limiting secondary injury, and improving functional recovery after intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH). Trials increasingly pursue rapid hemostatic agents, targeted neuroprotectants, and device-based minimally invasive clot evacuation to shorten disability and lower mortality.
Hemostatic and anti-expansion strategies (reversal agents, factor concentrates, and novel transferrable hemostats) aim to stabilize patients early and…
Cachexia Clinical Trials Analysis 2025: Metabolic Modulators, Anabolic Therapies …
DelveInsight's "Cachexia - Clinical Trials Analysis, 2025" examines a diverse development landscape targeting the complex metabolic, inflammatory, and neurohormonal drivers of cancer- and disease-related wasting. Given cachexia's strong association with poor survival, treatment intolerance, and reduced quality of life, trials increasingly measure both anabolic endpoints (lean body mass, muscle strength) and patient-centered outcomes (physical function, fatigue, appetite).
Late-stage and registration-enabling programs span ghrelin agonists and appetite stimulants, selective androgen receptor modulators…
More Releases for Chronic
Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030
This latest report researches the industry structure,…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Chronic Hepatitis Therapeutics Market - Empowering Liver Health, Defying Chronic …
Newark, New Castle, USA - new report, titled Chronic Hepatitis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Hepatitis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Hepatitis Therapeutics market. The report offers an overview of…
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…
